P21 Peptide
unknown riskAlso: P21 · BDNF-related peptide · Cortagen analog (partial)
P21 is a synthetic peptide claimed to mimic certain BDNF (brain-derived neurotrophic factor) activities by modulating the TRKB receptor pathway. Evidence is extremely limited, consisting primarily of a single mouse study and anecdotal human reports.
Reported Benefits
Neurogenesis
Single mouse study suggests neurogenesis in hippocampus.
Cognitive Enhancement
No controlled human data; anecdotal reports only.
Mechanism of Action
P21 is theorized to act as a BDNF partial agonist or modulator at TrkB receptors, potentially bypassing full BDNF binding while activating downstream neurogenic signaling pathways including MAPK/ERK and PI3K/Akt.
Key Clinical Studies
Kazim SF et al. (2017)
animal · Mouse Alzheimer model
P21 reduced Alzheimer pathology and improved cognition in transgenic mice
Overview
P21 represents the thin edge of the evidence spectrum — a peptide with essentially no published human data and extremely limited animal research. It is included here because it circulates in biohacking and nootropic communities, and accurate characterization of the evidence gap is important for informed decision-making.
Evidence Assessment
There is one published mouse study and no human clinical data. This is insufficient to draw any conclusions about efficacy or safety in humans. The mechanism proposed (BDNF modulation) is biologically plausible but unverified for this specific peptide.
Community vs. Scientific Reality
P21 has developed a following in online longevity and nootropic communities based on limited evidence. This pattern — a plausible mechanism, limited animal data, and strong community interest driving experimentation ahead of science — is common in the research peptide space and represents a meaningful risk to unsupervised users.
Our Recommendation
Given the extremely limited evidence base and unknown safety profile, P21 falls below the threshold for any evidence-based clinical consideration. We include it for reference and to accurately characterize the evidence gap.
Regulatory Status
Research OnlyNot FDA-approved; minimal published research; highly experimental
Safety Profile
Side Effects
- •Unknown — virtually no human safety data
Contraindications
- •Pregnancy
- •Active neurological/psychiatric conditions
Drug Interactions
- •None characterized
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe P21 Peptide?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →